Fort Worth-based TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical firm, is focused on the development and commercialization of medication products based on its patented Thin Film Freezing (TFF) technology platform in the US and Australia. The firm lays emphasis on inhaled dry powder drugs' development for pulmonary disease and conditions treatment. TFF Pharmaceuticals is currently working on TFF Voriconazole Inhalation Powder, designed for treating invasive pulmonary aspergillosis, and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials for preventing lung transplant rejection. Additionally, the company is creating other dry powder medicines, such as COVID-19 therapeutics' Augmenta monoclonal antibodies and completed Phase 1 clinical trials on TFF Niclosamide for COVID-19 disease treatment. The firm holds a license agreement with the University of Texas at Austin for creating inhaled dry powder medicines, a joint development partnership with Augmenta Bioworks, Inc., and a licensing and collaboration agreement with UNION therapeutics A/S.
TFF Pharmaceuticals's ticker is TFFP
The company's shares trade on the NASDAQ stock exchange
They are based in Austin, Texas
There are 1-10 employees working at TFF Pharmaceuticals
It is tffpharma.com
TFF Pharmaceuticals is in the Healthcare sector
TFF Pharmaceuticals is in the Biotechnology industry
The following five companies are TFF Pharmaceuticals's industry peers: